Christine Fisher
Plastic and Reconstructive Surgery · Austin, TXNPI 1265634935
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.6%), food and beverage and other — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by AbbVie at 56.7% of the total. Reporting peaked in 2019 at $14,740 and has fallen 96.6% since, to $494 in 2025. Among plastic and reconstructive surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $226.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Surgical Innovation Associates, Inc.$3K
- Acell, Inc.$3K
- Merz North America, Inc.$640
- Sientra, Inc.$578
- Integra Lifesciences Corporation$535
- plus $2K from 13 others
What the payments were for
- Consulting fees$10,89047%
- Speaking & faculty fees$2001%
- Food & beverage$5,76225%
- Education$2,90612%
- Entertainment$630%
- Other$3,54115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $13,257 |
| Surgical Innovation Associates, Inc. | 2 | $3,215 |
| Acell, Inc. | 1 | $2,906 |
| Merz North America, Inc. | 5 | $640 |
| Sientra, Inc. | 5 | $578 |
| Integra Lifesciences Corporation | 3 | $535 |
| Bard Peripheral Vascular, Inc. | 6 | $532 |
| Davol Inc. | 10 | $378 |
| Mentor Worldwide LLC | 8 | $277 |
| Motiva USA, LLC | 3 | $236 |
| Galderma Laboratories, L.p. | 2 | $186 |
| Axogen | 3 | $178 |
| Musculoskeletal Transplant Foundation Inc. | 3 | $157 |
| TELA Bio, Inc. | 2 | $154 |
| Argentum Medical | 1 | $63 |
| Kerecis Limited | 1 | $21 |
| KCI USA, Inc. | 1 | $20 |
| Acelrx Pharmaceuticals, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,362 in reported general payments places this provider in the 90th percentile of 378 plastic and reconstructive surgery providers in Texas.
See all plastic and reconstructive surgery providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 14 | $465 |
| Montelukast Sodium | 15 | $132 |
| Ondansetron OdtOndansetron | 14 | $97 |
| Gabapentin | 11 | $38 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in Austin
- Alina SholarAustin$110K
- Jeffery HallAustin$42K
- Rocco PiazzaAustin$39K
- Richard HopperAustin$27K
- Adam WeinfeldAustin$20K
- Aldona SpiegelHouston$759K
- Charles ButlerHouston$227K
- Michael KlebucHouston$204K
- Joshua LemmonRichardson$118K
- Patrick GarveyHouston$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.